| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/DOM.12226 |
| P698 | PubMed publication ID | 24148209 |
| P2093 | author name string | T R Einarson | |
| M Garg | |||
| V Kaur | |||
| M E H Hemels | |||
| P2860 | cites work | Determinants of weight gain in the action to control cardiovascular risk in diabetes trial | Q37022597 |
| The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. | Q37022665 | ||
| Weighting composite endpoints in clinical trials: essential evidence for the heart team | Q37115639 | ||
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Q37235840 | ||
| Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial | Q37348811 | ||
| Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field | Q37692734 | ||
| Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. | Q37878715 | ||
| Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes | Q37937592 | ||
| The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. | Q37940036 | ||
| Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. | Q37940567 | ||
| Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study | Q38044043 | ||
| Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. | Q39360286 | ||
| DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks | Q40718093 | ||
| Clinical perspectives on the use of composite endpoints | Q41668413 | ||
| Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks | Q41831179 | ||
| Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia | Q42613301 | ||
| A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin | Q42846868 | ||
| Evidence-based urology in practice: composite endpoints | Q43018768 | ||
| A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study | Q43034890 | ||
| Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial | Q43086322 | ||
| Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes | Q43187035 | ||
| Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme | Q44383427 | ||
| Efficacy of the Roux-en-Y gastric bypass compared to medically managed controls in meeting the American Diabetes Association composite end point goals for management of type 2 diabetes mellitus | Q44579854 | ||
| Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy | Q46173840 | ||
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial | Q46344895 | ||
| Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes | Q46401219 | ||
| Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide | Q47381999 | ||
| Pros and Cons of Composite Endpoints in Anesthesia Trials | Q48331262 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. | Q51382777 | ||
| Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. | Q51382898 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Q51478110 | ||
| Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. | Q51601217 | ||
| Combining composite endpoints: counterintuitive or a mathematical impossibility? | Q52020947 | ||
| Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations | Q22241134 | ||
| Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial | Q28277510 | ||
| Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial | Q28286240 | ||
| Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial | Q28287325 | ||
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
| The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study | Q33606579 | ||
| Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. | Q33785308 | ||
| Long-term effects of intensive glucose lowering on cardiovascular outcomes | Q33851861 | ||
| Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) | Q33854032 | ||
| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 | ||
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study | Q34598940 | ||
| The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone | Q34608300 | ||
| Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial | Q34610019 | ||
| Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone | Q34613240 | ||
| One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr | Q34893192 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes | Q35634210 | ||
| Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study | Q35688369 | ||
| Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets | Q36047167 | ||
| Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial | Q36249636 | ||
| Some issues with composite endpoints in clinical trials | Q36324876 | ||
| Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity | Q36498624 | ||
| Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks | Q36670931 | ||
| Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency | Q36782645 | ||
| Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas | Q36782811 | ||
| Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns | Q36851212 | ||
| Insulin-associated weight gain in diabetes--causes, effects and coping strategies | Q36966075 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 492-499 | |
| P577 | publication date | 2013-11-08 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Composite endpoints in trials of type-2 diabetes | |
| P478 | volume | 16 |
| Q91409675 | Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis |
| Q47182784 | Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes |
| Q37334002 | Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme |
| Q42180667 | Antioxidant strategies in the management of diabetic neuropathy. |
| Q47296986 | Blinded sample size recalculation in clinical trials with binary composite endpoints |
| Q58612825 | CANadian CAnagliflozin Registry: Effectiveness and Safety of Canagliflozin in the treatment of Type 2 diabetes mellitus in Canadian Clinical Practice |
| Q47326370 | Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus |
| Q40966874 | Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial |
| Q51020788 | Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes? |
| Q37257372 | Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. |
| Q89888252 | Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial |
| Q39892657 | Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease |
| Q47148933 | Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes. |
| Q55284804 | Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. |
| Q38931610 | Sex and age discrepancy of HbA1c and fetal hemoglobin determined by HPLC in a large Chinese Han population |
| Q36989681 | Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin |
Search more.